Lung cancer (Amsterdam, Netherlands) · 2025
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Murata Daiki, Azuma Koichi, Murotani Kenta, Ito Kazuhiro, Nomizo Takashi, Yamada Kazuhiko, Imabayashi Tatsuya, Iwanaga Kentaro, Chibana Kenji, Ota Takayo, Nishii Yuuya, Nakao Akira, Okada Asuka, Hamai Kosuke, Tanimura Keiko, Yoshimine Kohei, Tamura Yosuke, Takaki Ryuichiro, Goto Yasuhiro, Hibino Makoto, Oba Tomohiro, Sumi Toshiyuki, Kaneda Hiroyasu, Nishioka Naoya, Yamada Tadaaki, Takayama Koichi
Аннотация
BACKGROUND: For patients with advanced or recurrent non-small cell lung cancer (NSCLC) and PD-L1 < 1 %, a combination of an anti-CTLA-4 and anti-PD-1 antibody with and without platinum-based chemotherapy are used as a first-line treatment. Although the combined use of anti-CTLA-4 antibody has favorable therapeutic efficacy, increased incidence and severity of immune-related adverse events, including immune checkpoint inhibitor-induced interstitial lung disease (ICI-ILD), remains a challenge.
METHODS: A multicenter retrospective study of patients with advanced or recurrent NSCLC and PD-L1 < 1 % who received immune checkpoint inhibitors as a first-line treatment. The primary and secondary endpoints were incidence and prognostic impact, respectively, of ICI-ILD.
RESULTS: The cohort included 376 patients, with 119 and 257 receiving a CTLA-4 regimen and non-CTLA-4 regimen, respectively. The ICI-ILD incidence tended to be higher in patients treated with the CTLA-4 regimen, but the difference from the non-CTLA-4 regimen was not significant. Patients with ICI-ILD treated with the CTLA-4 regimen tended to have longer progression-free survival and overall survival than those who received non-CLTLA-4 treatment, but the difference was not significant.
CONCLUSION: For patients with NSCLC and PD-L1 < 1 %, the incidence of ICI-ILD tended to be higher in CTLA-4 regimens, and survival of patients with ICI-ILD tended to be longer for CTLA-4 regimens than for non-CTLA-4 regimens. Although the incidence of ICI-ILD in patients given CTLA-4 regimens tended to be higher than in those given non-CTLA-4 regimens, development of ICI-ILD does not necessarily negatively impact survival.
METHODS: A multicenter retrospective study of patients with advanced or recurrent NSCLC and PD-L1 < 1 % who received immune checkpoint inhibitors as a first-line treatment. The primary and secondary endpoints were incidence and prognostic impact, respectively, of ICI-ILD.
RESULTS: The cohort included 376 patients, with 119 and 257 receiving a CTLA-4 regimen and non-CTLA-4 regimen, respectively. The ICI-ILD incidence tended to be higher in patients treated with the CTLA-4 regimen, but the difference from the non-CTLA-4 regimen was not significant. Patients with ICI-ILD treated with the CTLA-4 regimen tended to have longer progression-free survival and overall survival than those who received non-CLTLA-4 treatment, but the difference was not significant.
CONCLUSION: For patients with NSCLC and PD-L1 < 1 %, the incidence of ICI-ILD tended to be higher in CTLA-4 regimens, and survival of patients with ICI-ILD tended to be longer for CTLA-4 regimens than for non-CTLA-4 regimens. Although the incidence of ICI-ILD in patients given CTLA-4 regimens tended to be higher than in those given non-CTLA-4 regimens, development of ICI-ILD does not necessarily negatively impact survival.